Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.6394
-0.0393 (-5.79%)
At close: Jan 21, 2026, 4:00 PM EST
0.6400
+0.0006 (0.09%)
After-hours: Jan 21, 2026, 7:59 PM EST
Femasys Employees
As of December 31, 2024, Femasys had 71 total employees, including 69 full-time and 2 part-time employees. The number of employees increased by 37 or 108.82% compared to the previous year.
Employees
71
Change (1Y)
37
Growth (1Y)
108.82%
Revenue / Employee
$29,035
Profits / Employee
-$278,891
Market Cap
37.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 71 | 37 | 108.82% | 69 | 2 |
| Dec 31, 2023 | 34 | -2 | -5.56% | 32 | 2 |
| Dec 31, 2022 | 36 | 7 | 24.14% | 34 | 2 |
| Dec 31, 2021 | 29 | 3 | 11.54% | 27 | 2 |
| Dec 31, 2020 | 26 | 0 | - | 24 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FEMY News
- 8 days ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 4 weeks ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 2 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 2 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 3 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 4 months ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 4 months ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 5 months ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire